 Patent Application Title |
Patent App Num. |
Date |
 Crystalline salts of quinoline compounds and methods for preparing them | 20130123301 | 20130516 |
 A crystalline salt of formula (II) and a process for preparing said salt.
... |
| Multiphoton activable quinoline derivatives, their preparation and their uses | 20130116281 | 20130509 |
 The present invention relates to multiphoton activable organic compounds responding to the following formula (I). The present invention also relates to a method of synthesizing the compounds of the invention, to an aqueous solution comprising at least one compound of the invention, and to their specific uses. The present invention also concerns a method of liberating organic ligands, said method involving the step of irradiating a compound according to the invention.
... |
| Quinoline derivatives and uses of the same | 20130096157 | 20130418 |
 wherein, R1 is a substituted or unsubstituted phenyl group, R2 is a halogen, and R3 is a substituted or unsubstituted phenyl group, and one of the carbon atoms in the phenyl ring of the phenyl group is optionally substituted by a nitrogen atom (N). The quinoline derivative can efficiently inhibit cancer cell proliferation and can be used for treating cancer, especially for treating cancers related to the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway and/or the mitogen-activated protein kinase (MAPK) pathway.
... |
| Controlled cure aliphatic laminating adhesive using non-migrating blocking agents for organometallic catalysts | 20130078473 | 20130328 |
 A two component polyurethane adhesive composition having one or more polyols as a first component and one or more isocyanates as a second component. The composition also comprises a catalyst and a hydroxyalkyl-8-hydroxy quinoline blocking agent to delay the initial part of the curing reaction. The blocking agent links to the adhesive matrix during cure. The composition provides long open time, improved wet out of the substrates to be bonded, a rapid cure rate and bonding of the blocking agent to the cured adhesive matrix. The adhesive is useful to bond layers of a flexible food pouch sheet. Also a flexible food pouch made using the adhesive.
... |
| Amino-quinolines as kinase inhibitors | 20130053375 | 20130228 |
 wherein R1, R2 and A are as defined herein, and methods of making and using the same.
... |
Subscribe to updates on this page: Quinoline RSS  |
| Materials for organic light emitting diode | 20130032785 | 20130207 |
| Organometallic compounds comprising a phenylquinoline or phenylisoquinoline ligand having the quinoline or isoquinoline linked to the phenyl ring of the phenylquinoline or phenylisoquinoline, respectively, via two carbon atoms. These compounds also comprise a substituent other than hydrogen and deuterium on the quinoline, isoquinoline or linker. These compounds may be used as red emitters in phosphorescent OLEDs. In particular, these compounds may provide stable, narrow and efficient red emission.
... |
| 7,11-methanocycloocta [b] quinoline derivative as highly functionalizable acetylcholinesterase inhibitors | 20130029941 | 20130131 |
| and a method for preparing such compounds and their use for treating neurological diseases in which the level of acetylcholine is affected such as Alzheimer's disease.
... |
| Methods of preparing quinoline derivatives | 20130030172 | 20130131 |
| n2 is 0-2.
... |
| Catalyst system based on quinoline donors | 20130023634 | 20130124 |
| with the proviso that the catalyst system is not treated with alumoxanes.
... |
| Quinoline and quinoxaline derivatives as kinase inhibitors | 20130018057 | 20130117 |
| A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
... |
| System for improved delivery of gene modulating compounds | 20130011448 | 20130110 |
| It also relates to the use of the system in diagnosis of diseases, as research tool and as a targeting system, a composition comprising the system and especially a pharmaceutical composition, a material covered with the system and a material having the delivery systems within the material.
... |
| Trpv4 antagonists | 20130012499 | 20130110 |
| The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
... |
| Bi-functional quinoline analogs | 20130012504 | 20130110 |
| R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.
... |
Subscribe to updates on this page: Quinoline RSS |
| Quinoline and quinoxaline derivatives as kinase inhibitors | 20130012517 | 20130110 |
| A series of quinoline and quinoxaline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
... |
| Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-ht6 receptor | 20130005703 | 20130103 |
| The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X′, Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.
... |
| Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | 20120309782 | 20121206 |
| therapeutic methods, compositions, and medicaments related thereto are also disclosed.
... |
| Pesticidal mixtures | 20120289404 | 20121115 |
| The present invention relates to an agrochemical mixture for increasing the health of a plant, comprising as active ingredients a herbicidal compound (I) selected from the group consisting of: benzoic acids, pyridine carboxylic acids, quinoline carboxylic acids, and_benazolin-ethyl; and a fungicidal compound (II) in synergistically effective amounts. The present invention further relates to a method for improving the health of a plant, wherein the plant, the locus where the plant is growing or is expected to grow or plant propagation material from which the plant grows is treated with an effective amount of a mixture as defined above. In addition, the invention relates to the use of a mixture as defined above for synergistically increasing the health of a plant.
... |
| Plant disease control composition and method for controlling plant disease by applying the same | 20120282349 | 20121108 |
| (wherein R1, R2: an alkyl which may be substituted, an aryl which may be substituted, etc.; R3, R4: H, an alkyl which may be substituted, etc.; X: halogen, an alkyl which may be substituted, etc.; Y: halogen, alkyl, etc.; n: 0 to 4; m: 0 to 6) or a salt thereof, and at least one of fungicidal compounds selected from the group consisting of a Strobilurin series compound, a triazole series compound, etc., as effective ingredients.
... |
| Chiral phosphorus compound | 20120264940 | 20121018 |
| wherein R1, R2, R3, R4, R5 are chiral or achiral organic residues which are derived from substituted or unsubstituted straight or branched chain or cyclic aliphatic or aromatic groups and which, in the case of the pairs R1/R2 and R4/R5, may be interconnected. Further, the invention relates to methods for the synthesis of chiral phosphorus compounds of general formula (I) and their use as catalyst components in processes for the preparation of optically active products.
... |
| Quinoline amide m1 receptor positive allosteric modulators | 20120252808 | 20121004 |
| The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
... |
| Crystal form of quinoline compound and process for its production | 20120245200 | 20120927 |
| The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form A, thereby to obtain a drug substance excellent in stability.
... |
| Imidazo [4, 5-c] quinoline derivatives as bromodomain inhibitors | 20120232074 | 20120913 |
| and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.
... |
| Methods of preparing and using quinazoline and quinoline derivatives | 20120225872 | 20120906 |
| A method for treating cancer or inhibiting growth of cancer cells including administering to a patient mammal in need thereof a pharmaceutical preparation including the compound. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal including administering to a mammal a pharmaceutical preparation including the compound.
... |
| Novel 2-substituted quinoline derivatives, and method for preparing same | 20120225903 | 20120906 |
| The invention relates to 2-substituted quinoline derivatives, to a method for preparing same, and to the use thereof for drug production, particularly for treating infections caused by protozoa, such as leishmaniases, trypanosomiases, toxoplasmoses, and/or infections caused by retroviruses such as, for example, HIV or HTLV.
... |
| Germanium-containing red emitter materials for organic light emitting diode | 20120217868 | 20120830 |
| Organometallic compounds comprising a germanium-containing substituent are provided. The compounds may be used in organic light emitting devices to provide improved device efficiency, line shape and lifetime. In particular, the compounds comprise a phenylquinoline or phenylisoquinoline ligand having a germanium-containing substituent on the quinoline or isoquinoline portion of the ligand. These compounds may be advantageously used as red emitters in the emissive layer of organic light emitting devices.
... |
| Substituted quinoline compounds and methods of use | 20120219522 | 20120830 |
| The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
... |
| Novel quinoline compound, and composition containing centipede extract or compounds isolated therefrom for prevention and treatment of cardiovascular disease | 20120220626 | 20120830 |
| The present invention relates to a composition for the prevention and treatment of cardiovascular diseases containing the novel quinoline compound, the centipede extracts or compounds isolated from the extracts. The novel quinoline compound, the centipede extracts or a quinoline compound and a phenol compound isolated from the extracts of the invention exhibit excellent LDL-antioxidant activity, ACAT inhibiting activity, and anti-inflammatory activities, so that they can be included as an effective ingredient in a composition for the prevention and treatment of cardiovascular disease including hyperlipidemia, atherosclerosis, coronary heart disease, and myocardial infarction mediated by LDL-oxidation, cholesteryl ester synthesis and accumulation, and inflammation.
... |
| Enantioselective preparation of quinoline derivatives | 20120220775 | 20120830 |
| wherein M, L, X, R1, R2 and R3 have the meanings as indicated in the specification.
... |
| Immune enhancement composition and kit and use thereof | 20120214834 | 20120823 |
| An immune enhancement composition is disclosed. The immune enhancement composition includes rapamycin, substituted quinoline and a pharmaceutically acceptable carrier, diluent, excipient or a combination thereof. An immune enhancement kit containing the two aforementioned compounds and a use of a combination containing the two aforementioned compounds as an immune enhancement composition are also disclosed. The application of the composition, kit and use is advantageous for promoting the activity of the immune system.
... |
| Sensitizer, pharmaceutical composition, kit and use for target therapy | 20120214836 | 20120823 |
| A target therapy sensitizer including rapamycin and substituted quinoline is disclosed. In addition, a pharmaceutical composition containing the sensitizer, a target therapy sensitization kit containing the two aforementioned compounds, and a use of a combination of the two aforementioned compounds as a target therapy sensitizer are also disclosed. The application of the target therapy sensitizer, pharmaceutical composition, kit and use is advantageous for improving the treatment effect of target therapies.
... |
